Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007196
Chunk: 20

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 20
---
 Warrants and May 2023 Placement Agent Warrants after receiving required shareholder
approval of the allotment of, and disapplication of pre-emption rights with respect to the Ordinary Shares to be issued under the warrants
at our June GM.

Between
June 20, 2023, and December 31, 2024, we have issued 166,017,700 ordinary shares upon the exercise of Series C Warrants issued in the
May 2023 registered direct offering.

On
July 5, 2023, we effected a ratio change to the Depositary Shares, pursuant to which the ratio of ordinary shares to Depositary Shares
was changed such that one Depositary Share represented 400 ordinary shares. Our ordinary shares were not affected by this change and no
fractional Depositary Shares were issued.

On November 22, 2023, we entered into a series of agreements with (1) Adhera Therapeutics, Inc. and certain of its secured noteholders, or the Secured Noteholders, and (1) Melior Pharmaceuticals I, Inc., or Melior. On December 21, 2023, in connection with the closing under the agreements, we issued (A) an
aggregate of (i) 8,997 Depositary Shares to certain of the Secured Noteholders and (ii) 90,999 pre-funded warrants to purchase Depositary
Shares to certain of the Secured Noteholders, or the December 2023 Private Placement Pre-Funded Warrants, and (B) 14,177 Depositary Shares
to Melior. Between December 21, 2023 and April 1, 2025, we have issued 738,002,400 Ordinary Shares upon the exercise of December 2023
Private Placement Pre-Funded Warrants issued to the Secured Noteholders.

On December 21, 2023, we completed the closing of an underwritten public offering,
pursuant to which we issued and sold (i) 43,555 Class A units, or Class A Units, at a public offering price of $50.00 per Class A Unit,
with each Class A Unit consisting of (a) one Depositary Share, (b) one Series E warrant, or Series E Warrant, and (c) one Series F warrant,
or Series F Warrant, and (ii) 76,447 Class B units, or Class B Units, at a public offering price of $26.9999 per